# A Non-interventional Prospective Study of 1-st Line Treatment Approaches in OVArian Cancer Patients With HRD+ Status in Russian Federation

> **NCT05918042** · — · ACTIVE_NOT_RECRUITING · sponsor: **AstraZeneca** · enrollment: 400 (estimated)

## Conditions studied

- Ovarian Cancer

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT05918042
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2023-06-21
- **Primary completion:** 2025-07-31
- **Final completion:** 2025-07-31
- **Target enrollment:** 400 (ESTIMATED)
- **Last updated:** 2025-07-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05918042

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05918042, "A Non-interventional Prospective Study of 1-st Line Treatment Approaches in OVArian Cancer Patients With HRD+ Status in Russian Federation". Retrieved via AI Analytics 2026-09-08 from https://api.ai-analytics.org/clinical/NCT05918042. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*